Cosmos Health Targets $200M Revenue by 2029 on U.S. Expansion, AI-Driven R&D — Cosmos Health Inc.

Event summary

Cosmos Health reported record FY2025 revenue of $65.3M, up 20% YoY, with Q1 2026 revenue hitting $17.9M, up 31% YoY.
The company projects $200.6M revenue, $44.2M Adjusted EBITDA, and $92.3M stockholders' equity by 2029.
U.S. market entry is active, with projected annualized revenue exceeding $20M at ~75% gross margins within 12–18 months.
Cosmos Health is pursuing up to €25M in financing from the European Investment Bank for R&D.
C-Scrub is expanding into the $69B global animal health market.

The big picture

Cosmos Health is pivoting from a distribution-focused model to a vertically integrated, AI-driven healthcare platform. The company's strategic shift toward higher-margin proprietary products and U.S. expansion positions it to compete in the $164B American nutraceuticals market and the $299B global weight management sector. The pursuit of €25M in financing from the European Investment Bank underscores the company's ambition to scale its R&D pipeline and strengthen its balance sheet.

What we're watching

Execution Risk: Whether Cosmos Health can sustain its projected 38% YoY growth rate through 2026 and beyond.
Market Expansion: How the U.S. market will scale and whether it can meet the projected $20M annualized revenue within 12–18 months.
R&D Pipeline: The pace at which the AI-driven Cloudscreen platform and nanotechnology investments translate into commercial products.